— Research monograph
Thymosin Alpha-1
A 28-amino-acid immunomodulatory peptide approved abroad as Zadaxin.
Updated
- Class
- 28-amino-acid N-acetylated peptide (acetyl-Ser-Asp-Ala-Ala-Val-Asp-Thr-Ser-Ser-Glu-Ile-Thr-Thr-Lys-Asp-Leu-Lys-Glu-Lys-Lys-Glu-Val-Val-Glu-Glu-Ala-Glu-Asn)
- Half-life (research)
- ~2 hr (subcutaneous administration, preclinical models).
- Origin
- Isolated from bovine thymus extract (Thymosin Fraction 5) by Allan Goldstein at the Albert Einstein College of Medicine in the early 1970s; sequence first published in 1977. Approved for clinical use as Zadaxin in over 35 countries for chronic hepatitis B and as a vaccine adjuvant.
- Solubility
- Highly water-soluble. Physicochemical context only. Merit Sciences publishes no reconstitution or preparation procedures.
What is Thymosin Alpha-1?
Thymosin Alpha-1 (Tα1) is a 28-amino-acid N-acetylated peptide derived from prothymosin alpha (ProTα). Among the family of thymic peptides, Tα1 is the most extensively characterized in the published immunology and infectious-disease research literature.
The peptide is identical in sequence across mammalian species, suggesting strong evolutionary conservation. In approved clinical use abroad it is administered subcutaneously; in research contexts it is most commonly investigated for effects on T-cell maturation, dendritic-cell function, and innate-immune signaling.
How does Thymosin Alpha-1 work?
Toll-like receptor 9 (TLR9) and MyD88-dependent signaling pathway activation has been reported as the dominant proximal mechanism. Downstream effects include dendritic-cell maturation, enhanced Th1 cytokine production, and modulation of regulatory T-cell populations in preclinical models.
Research applications
- Immunomodulation research
- Antiviral pathway investigation
- T-cell maturation studies
- Vaccine adjuvant research
- TLR9 signaling pharmacology
Thymosin Alpha-1 at Merit
Research review on The Assay, Merit’s editorial publication: Thymosin Alpha-1: Approved Abroad, Unapproved in the US
Form & storage
Thymosin Alpha-1 ships as a sealed, lyophilized (freeze-dried) powder. Highly water-soluble. Physicochemical context only. Merit Sciences publishes no reconstitution or preparation procedures. Store sealed, light-protected, and follow your institution’s handling procedures for research materials.
Frequently asked questions
What is Thymosin Alpha-1?
Thymosin Alpha-1 (Tα1) is a 28-amino-acid N-acetylated peptide derived from prothymosin alpha (ProTα). Among the family of thymic peptides, Tα1 is the most extensively characterized in the published immunology and infectious-disease research literature. Merit supplies it as a lyophilized research compound for research use only, not for human or veterinary use.
How does Thymosin Alpha-1 work?
Toll-like receptor 9 (TLR9) and MyD88-dependent signaling pathway activation has been reported as the dominant proximal mechanism. Downstream effects include dendritic-cell maturation, enhanced Th1 cytokine production, and modulation of regulatory T-cell populations in preclinical models. Mechanistic descriptions summarize published preclinical findings and are not clinical claims.
What is the half-life of Thymosin Alpha-1?
~2 hr (subcutaneous administration, preclinical models). Values reflect preclinical or research-context reports, not clinical pharmacokinetics.
Is Merit Thymosin Alpha-1 for human use?
No. It is sold strictly for research use only: not for human or veterinary use, and not for diagnostic or therapeutic use.
Is Thymosin Alpha-1 FDA-approved?
Thymosin alpha-1 (thymalfasin) is approved as a prescription drug in some countries outside the United States but has never been approved by the FDA. Supplied for research use only.
How is each batch of Thymosin Alpha-1 tested?
Every Merit batch is tested by an independent laboratory for identity and HPLC purity before it is listed, and Merit identifies batches by date rather than by lot number. Current certificates: Thymosin Alpha-1 10 mg, March 2026 batch, 99.618% purity (meritsciences.com/coa/MRT-2603-02).
Regulatory status checked October 22, 2026 against: Drugs@FDA, FDA Category 2 list.
References
- From lab to bedside: emerging clinical applications of thymosin α1. Goldstein AL, Goldstein AL. Expert Opinion on Biological Therapy, 2009 · PMID 19392576
- Thymosin alpha 1: from bench to bedside. Garaci E, Pica F, Serafino A, et al.. Annals of the New York Academy of Sciences, 2007 · PMID 17600290
For research use only. Not for human or veterinary use. Reference information summarized from published literature, not medical advice.